Jaguar Health Inc. (NASDAQ: JAGX) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its wholly owned subsidiary, Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. The company’s Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and is the only oral plant-based prescription medicine approved under FDA Botanical Guidance. For more information. visit the company’s website at www.jaguar.health
To watch the presentation, visit https://ibn.fm/NobleCon17Registration
To view IBN’s virtual coverage of Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference, visit https://ibn.fm/NobleCon17
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN used social media and syndicated articles to maximize the visibility of NobleCon17.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]